Cancer Biotech Co. Eyes $182M IPO
By Grace Dixon · January 5, 2026, 7:31 PM EST
A company developing new drugs for treating cancer disclosed Monday it is looking to raise roughly $182 million in an initial public offering guided by Paul Hastings LLP and Davis Polk &...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login